IOVANCE BIOTHERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-06.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2021-05-06
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2021-03-31 was 0.00%.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2020-03-31 was 0.00%.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2019-03-31 was 0.00%.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2018-03-31 was 0.00%.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2019 was 0.00%.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2018 was 0.00%.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2017 was 0.00%.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2016 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2021-03-31 | 0.00% 10-Q · filed 2021-05-06 | |||
| 2020-09-30 | 0.00% 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | 0.00% 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | 0.00% 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | 0.00% 10-K · filed 2020-02-25 | |||
| 2019-09-30 | 0.00% 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | 0.00% 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | 0.00% 10-Q · filed 2020-05-05 | |||
| 2018-12-31 | 0.00% 10-K · filed 2020-02-25 | |||
| 2018-09-30 | 0.00% 10-Q · filed 2019-11-04 | |||
| 2018-06-30 | 0.00% 10-Q · filed 2019-08-01 | |||
| 2018-03-31 | 0.00% 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | 0.00% 10-K · filed 2020-02-25 | |||
| 2017-06-30 | 0.00% 10-Q · filed 2018-08-07 | |||
| 2017-03-31 | 0.00% 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | 0.00% 10-K · filed 2019-02-28 | |||
| 2016-09-30 | 0.00% 10-Q · filed 2016-11-04 | 0.00% 10-Q · filed 2016-11-04 | ||
| 2015-12-31 | 0.00% 10-K · filed 2018-03-12 | |||
| 2015-09-30 | 0.00% 10-Q · filed 2016-11-04 | 0.00% 10-Q · filed 2016-11-04 | ||
| 2014-12-31 | 0.00% 10-K · filed 2017-03-09 | |||
| 2014-06-30 | 0.00% 10-Q · filed 2014-08-08 | |||
| 2014-03-31 | 0.00% 10-Q · filed 2014-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |